​These findings and the previous demonstration that MUC1-C regulates DNA methylation hold important implications for MUC1-C as a target for reprogramming the cancer cell epigenome. 

Genus Oncology completes enrollment to the Phase Ib trial of GO-203 in combination with decitabine for patients with AML.

​Based on an acceptable safety profile and promising clinical activity, the combination has now been advanced to a Phase IIa study at the BIDMC and DFCI to assess therapeutic efficacy.